Integria expands on Warwick facility

Media Release

12 February, 2020

In growth initiative, Integria invests in expanded Warwick production facility

Natural medicines and therapies company Integria Healthcare today announced plans for an additional $7 million investment in its Warwick production site.

The investment will fund the expansion of the facility and establishment of a fully integrated processing and packing facility, allowing more agile and dynamic operations which will provide significant potential for future growth and innovation.

The facility will specialise in highest quality herbal medicines and therapeutic, Essential Oil remedies and products.

Integria will close its site in Ballina by the end of 2020 and conduct a phased transfer of operations to Warwick.

Consolidation of production at Warwick will give Integria the ability to innovate more quickly and be more agile in bringing new products to market in response to changing consumer demand.

Integria remains fully committed to its portfolio of natural medicine brands including its flagship MediHerb® herbal practitioner brand and Thursday Plantation® tea tree oil products, which are currently packaged in Ballina. Integria products from Warwick will be sold throughout Australia, New Zealand, China, South East Asia, North America and Europe.

Integria has already invested $21m in the Warwick site over the last five years as part of its strategy to build a sustainable business, fit for future market requirements.

Integria Healthcare CEO, Michael Bracka, said the expansion of Warwick was an important step in positioning Integria’s portfolio of brands for sustained growth.

“Integria Healthcare is a first-class provider of natural therapies and we’re determined to stay at the forefront of a competitive and fast-changing market.

“The investment in our production capabilities is not just in capacity but also in new formats and new innovations. A fully integrated facility will help us drive innovation, quality and scientific research,” he said.

Plans to develop the Warwick site have already commenced, including site works for construction of an expanded factory. It is expected the transfer of production operations from Ballina to Warwick will be completed by the end of the year.

Source: Integria Healthcare.


Must Read

Call for universal HPV vaccination after possible link to prostate cancer

Human papilloma viruses (HPVs) may also have a causal role in prostate cancer, according to a review published in the journal Infectious Agents and...